This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Colozza, M. Articles by Piccart, M. J. Search for Related Content PubMed PubMed Citation Articles by Colozza, M. Articles by Piccart, M. J.

Breast Cancer: Achievements in Adjuvant Systemic Therapies in the Pre-Genomic Era

^a S.C. Oncologia Medica, Azienda Ospedaliera, Perugia, Italy; ^b Medical Oncology Clinic, Jules Bordet Institute, Brussels, Belgium

Key Words. Breast cancer • Adjuvant • Chemotherapy • Endocrine therapy • Trastuzumab • Taxanes

Correspondence: Martine Piccart, M.D., Ph.D., Jules Bordet Institute, Boulevard de Waterloo, 125, 1000 Brussels, Belgium. Telephone: 32-2-541-3206; Fax: 32-2-538-0858; e-mail: martine.piccart{at}bordet.be

In recent decades, the use of adjuvant systemic therapies for early breast cancer has increased extensively and has most likely contributed to the decline in breast cancer mortality observed in the U.S. and in some European countries. The last few years have witnessed accelerated progress in the treatment of early breast cancer, with the introduction of taxanes and aromatase inhibitors and, most impressively, trastuzumab to the adjuvant portfolio. When compared with anthracycline-based regimens, the addition of taxanes to treatments for patients with node-positive breast cancer has shown benefits in disease-free survival and, in some trials, in overall survival; however, these drugs are not yet universally accepted as standard treatment. Significant improvements in endocrine therapy in both pre- and postmenopausal patients with endocrine-responsive disease have been made. In the postmenopausal setting, aromatase inhibitors have shown superiority over tamoxifen in a direct comparison upfront or when given in sequence after 2–5 years of tamoxifen, but the optimal modality of administration remains unclear. For premenopausal women, ovarian function suppression with luteinizing hormone-releasing hormone analogues combined with tamoxifen has generated similar results to cyclophosphamide, methotrexate, 5-fluorouracil (CMF)–based regimens. Recently, trastuzumab has had a dramatic impact on the evolution of human epidermal growth factor receptor 2 (HER-2)–positive early breast cancer treated with standard adjuvant modalities; specifically, relapses, including distant relapses, have been halved. In this review, we summarize these main achievements, discuss the currently available adjuvant treatment options for breast cancer patients, and emphasize the need for more efficient translational research to improve individual treatment tailoring.

This article has been cited by other articles:

				A. Merglen, H. M. Verkooijen, G. Fioretta, I. Neyroud-Caspar, V. Vinh-Hung, G. Vlastos, P. O. Chappuis, M. Castiglione, E. Rapiti, and C. Bouchardy Hormonal therapy for oestrogen receptor-negative breast cancer is associated with higher disease-specific mortality Ann. Onc., May 1, 2009; 20(5): 857 - 861. [Abstract] [Full Text] [PDF]

				A. Gondos, F. Bray, T. Hakulinen, H. Brenner, and the EUNICE Survival Working Group Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis Ann. Onc., March 1, 2009; 20(3): 564 - 573. [Abstract] [Full Text] [PDF]

				C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Clin. Chem., December 1, 2008; 54(12): e11 - e79. [Abstract] [Full Text] [PDF]

				C. Hudis and S. Modi Preoperative Chemotherapy for Breast Cancer: Miracle or Mirage? JAMA, December 12, 2007; 298(22): 2665 - 2667. [Full Text] [PDF]

				R. C. Cho, P. D. Cole, K.-J. Sohn, G. Gaisano, R. Croxford, B. A. Kamen, and Y.-I. Kim Effects of folate and folylpolyglutamyl synthase modulation on chemosensitivity of breast cancer cells Mol. Cancer Ther., November 1, 2007; 6(11): 2909 - 2920. [Abstract] [Full Text] [PDF]

				S. Verma and M. Clemons First-Line Treatment Options for Patients with HER-2 Negative Metastatic Breast Cancer: The Impact of Modern Adjuvant Chemotherapy Oncologist, July 1, 2007; 12(7): 785 - 797. [Abstract] [Full Text] [PDF]

				D. Gemmati, A. Ongaro, S. Tognazzo, L. Catozzi, F. Federici, E. Mauro, M. Della Porta, D. Campioni, A. Bardi, G. Gilli, et al. Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival Haematologica, April 1, 2007; 92(4): 478 - 485. [Abstract] [Full Text] [PDF]

				G. Ferretti, P. Papaldo, A. Fabi, P. Carlini, A. Felici, and F. Cognetti Adjuvant Trastuzumab with Docetaxel or Vinorelbine for HER-2-Positive Breast Cancer Oncologist, July 1, 2006; 11(7): 853 - 854. [Full Text] [PDF]